Published Technical Disclosure Archive

Intelligent Docetaxel Liposomal Injections for Personalized Cancer Treatment

Publication ID: 24-11857680_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Docetaxel Liposomal Injections for Personalized Cancer Treatment,” Published Technical Disclosure No. 24-11857680_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857680_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,680.

Summary of the Inventive Concept

The present invention relates to a novel system that integrates docetaxel liposomal injections with advanced technologies like AI, IoT, blockchain, and new materials to create a more effective and personalized cancer treatment approach.

Background and Problem Solved

The original patent provided a composition of docetaxel liposomal injection with high drug loading, but it had limitations in terms of targeted delivery, patient monitoring, and supply chain integrity. The new inventive concept addresses these limitations by incorporating synergistic combinations of distinct technologies to create a more powerful system.

Detailed Description of the Inventive Concept

The new system comprises a docetaxel liposomal composition, an AI-powered delivery mechanism that optimizes the composition's residence time in blood, an IoT-enabled monitoring system that tracks the patient's response to the treatment, a blockchain-secured tracking mechanism that ensures the authenticity and integrity of the composition throughout the supply chain, and a novel material for docetaxel liposomal compositions that enhances the composition's stability and bioavailability. The AI-driven dosing algorithm optimizes the composition's release profile based on the patient's individual needs.

Novelty and Inventive Step

The new claims introduce a synergistic combination of advanced technologies that create a more effective and personalized cancer treatment approach, which is not obvious from the original patent. The integration of AI, IoT, blockchain, and new materials with the docetaxel liposomal composition provides a novel and non-obvious solution.

Alternative Embodiments and Variations

Other ways to implement the inventive concept include using different AI algorithms for personalized dosing, integrating the system with wearable devices for real-time patient monitoring, or using alternative blockchain platforms for secure tracking. The novel material for docetaxel liposomal compositions could be modified to include other excipients or nanoparticles for enhanced stability and bioavailability.

Potential Commercial Applications and Market

The intelligent docetaxel liposomal injections have significant commercial potential in the oncology market, particularly in personalized cancer treatment. The system's ability to optimize treatment outcomes, reduce side effects, and ensure supply chain integrity makes it an attractive solution for pharmaceutical companies, hospitals, and patients.

CPC Classifications

SectionClassGroup
A A61 A61K9/127
A A61 A61K9/0019
A A61 A61K9/1277
A A61 A61K31/337
A A61 A61K47/24
A A61 A61K47/26
A A61 A61K47/28

Field of Art

Pharmaceutical nanotechnology, specifically liposomal drug delivery systems for oncological treatments, requiring advanced knowledge of pharmaceutical formulation, nanoparticle engineering, and drug encapsulation techniques

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist with expertise in liposomal drug delivery, holding a PhD or equivalent advanced degree, with specialized knowledge in nanoformulation, drug stability, and cancer treatment technologies

Obviousness Rationale

A PHOSITA would recognize that integrating advanced technologies like AI, IoT, and blockchain with existing liposomal drug delivery systems represents a predictable extension of known pharmaceutical innovation strategies. The core docetaxel liposomal composition remains substantially similar to the source patent, with technological enhancements that would be considered routine optimization by those skilled in the field. The proposed variations represent incremental improvements using standard interdisciplinary approaches common in modern pharmaceutical research.

Obvious Combinations & Variations

Source Patent Element
Docetaxel liposomal composition with specific weight percentages of components
PTD Variation
Adding nanocellulose-based excipients to enhance stability and bioavailability
Obviousness Reasoning
A PHOSITA would recognize that modifying liposomal excipients to improve drug delivery is a known technique, with predictable results in enhancing pharmaceutical performance
Source Patent Element
Liposomal composition with defined pH characteristics
PTD Variation
Implementing AI-driven dosing algorithm to optimize release profile
Obviousness Reasoning
Personalized drug delivery algorithms are a foreseeable technological progression in pharmaceutical formulation, representing an obvious application of computational methods to existing drug delivery systems
Source Patent Element
Targeted liposomal drug delivery for cancer treatment
PTD Variation
Integrating IoT-enabled monitoring system to track patient treatment response
Obviousness Reasoning
Incorporating real-time patient monitoring technologies is a logical extension of precision medicine approaches, representing an obvious combination of existing pharmaceutical and digital health technologies
Source Patent Element
Pharmaceutical composition with defined liposomal characteristics
PTD Variation
Blockchain-secured tracking mechanism for supply chain integrity
Obviousness Reasoning
Implementing blockchain for pharmaceutical supply chain authentication represents a predictable application of emerging digital verification technologies to existing pharmaceutical distribution methods
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in the Published Technical Disclosure (PTD) would be considered obvious to a Person Having Ordinary Skill In The Art in view of US Patent 11857680, as the proposed technological enhancements represent predictable combinations of known pharmaceutical formulation techniques with emerging digital technologies, lacking any non-obvious inventive step beyond routine optimization of existing liposomal drug delivery systems.

Original Patent Information

Patent NumberUS 11,857,680
TitleComposition of docetaxel liposomal injection with high drug loading
Assignee(s)SHILPA MEDICARE LIMITED